Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
28 hedge funds and large institutions have $7.09M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $7.42M → $7.09M (-$327K)
7% less funds holding
Funds holding: 30 → 28 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$847K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$262K |
| 3 |
Renaissance Technologies
New York
|
+$248K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$121K |
| 5 |
Squarepoint
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
-$443K |
| 2 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$179K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$138K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$30.3K |
OPNT Hedge Fund Activity: Q3 2020 in Review
28 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q3 2020, worth a combined $7.09M — down 4.4% from $7.42M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of OPNT and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 12 added.
The largest buyer was Wells Fargo, adding an estimated $847K. The largest seller was Fondren Management, cutting an estimated $443K.
- 28 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q3 2020, down from 30 in Q2 2020.
- Funds reported $7.09M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 4.4% quarter-over-quarter.
- 4 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 5 closed out, a net change of -1 holder.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Wells Fargo, an estimated $847K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Fondren Management, an estimated $443K sold.
Based on aggregated 13F filings for Q3 2020.